276 related articles for article (PubMed ID: 11908741)
1. Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation.
Leis J; Porter DL
Leuk Lymphoma; 2002 Jan; 43(1):9-17. PubMed ID: 11908741
[TBL] [Abstract][Full Text] [Related]
2. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
Miyamoto T; Fukuda T; Nakashima M; Henzan T; Kusakabe S; Kobayashi N; Sugita J; Mori T; Kurokawa M; Mori SI
Biol Blood Marrow Transplant; 2017 Jun; 23(6):938-944. PubMed ID: 28219836
[TBL] [Abstract][Full Text] [Related]
3. Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.
Kumar AJ; Vassilev P; Loren AW; Luger SM; Reshef R; Gill S; Smith J; Goldstein SC; Hexner E; Stadtmauer EA; Porter D; Frey NV
Am J Hematol; 2016 Jun; 91(4):426-9. PubMed ID: 26820493
[TBL] [Abstract][Full Text] [Related]
4. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.
Porter DL; Collins RH; Hardy C; Kernan NA; Drobyski WR; Giralt S; Flowers ME; Casper J; Leahey A; Parker P; Mick R; Bate-Boyle B; King R; Antin JH
Blood; 2000 Feb; 95(4):1214-21. PubMed ID: 10666193
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
7. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
Collins RH; Shpilberg O; Drobyski WR; Porter DL; Giralt S; Champlin R; Goodman SA; Wolff SN; Hu W; Verfaillie C; List A; Dalton W; Ognoskie N; Chetrit A; Antin JH; Nemunaitis J
J Clin Oncol; 1997 Feb; 15(2):433-44. PubMed ID: 9053463
[TBL] [Abstract][Full Text] [Related]
8. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
[TBL] [Abstract][Full Text] [Related]
9. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
10. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
12. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
13. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population.
Levine JE; Barrett AJ; Zhang MJ; Arora M; Pulsipher MA; Bunin N; Fort J; Loberiza F; Porter D; Giralt S; Drobyski W; Wang D; Pavletic S; Ringden O; Horowitz MM; Collins R
Bone Marrow Transplant; 2008 Aug; 42(3):201-5. PubMed ID: 18490913
[TBL] [Abstract][Full Text] [Related]
14. Donor leukocyte infusions in myeloid malignancies: new strategies.
Porter DL; Antin JH
Best Pract Res Clin Haematol; 2006; 19(4):737-55. PubMed ID: 16997180
[TBL] [Abstract][Full Text] [Related]
15. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapse after allogeneic BMT with donor leukocyte infusions in 16 patients.
Russell LA; Jacobsen N; Heilmann C; Simonsen AC; Christensen LD; Vindelov LL
Bone Marrow Transplant; 1996 Aug; 18(2):411-4. PubMed ID: 8864454
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
18. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.
Luznik L; Fuchs EJ
Cancer Control; 2002; 9(2):123-37. PubMed ID: 11965233
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation.
Grigg A; Kannan K; Schwarer AP; Spencer A; Szer J
Intern Med J; 2001; 31(1):15-22. PubMed ID: 11478351
[TBL] [Abstract][Full Text] [Related]
20. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: indications and dose escalation.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Ther Apher; 2001 Feb; 5(1):40-5. PubMed ID: 11258609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
